MNOV
MediciNova, Inc.
Healthcare · Biotechnology · NGM
$1.31
Data: 2026-05-14
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$67M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-3.30
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-25.5%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$9.00
+587% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 4 analysts covering this stock
About MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

https://medicinova.com

Country: United States Employees: 6 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.3% PASS
Debt must be below 33% of total assets
Cash Ratio
45.7% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.360
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0580
No positive edge detected — the data suggests staying out
Calmar Ratio
0.038
Drawdown risk outweighs the returns — higher risk profile
Annual Return
1.9%
Historical annualised return based on price data
Max Drawdown
-50.4%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
36
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.63
Less volatile than the market — more defensive
52W High
$1.96
33% below the year high
52W Low
$1.17
12% above the year low
Avg Volume
47,098
Average daily shares traded — higher means easier to buy and sell
Short Ratio
6.3
Days it would take all short sellers to cover — higher means more crowded
Short % Float
0.4%
Low short interest — limited bearish positioning
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.24
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.51
Moderate leverage — manageable
Current Ratio
8.16
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
8.11
Like current ratio but excludes inventory — stricter test
Gross Margin
7.6%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-2,038.0%
Profit from core operations before interest and tax
Free Cash Flow
$-6,088,045
Negative — the business is spending more than it generates
Revenue (TTM)
$409,657
Total revenue over the last 12 months
Net Income
$-11,997,957
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
4
Target High
$11.00
Target Median
$9.00
Target Low
$6.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.